Use of Donanemab in Early Symptomatic Alzheimer Disease

Affiliations

¹ Nathan S. Kline Institute for Psychiatric Research, NYU Grossman School of Medicine, Orangeburg, New York.
² Research and Development, Chiesi Farmaceutici, Parma, Italy.

Comment

Nunzio Pomara et al. JAMA. 2023.

. 2023 Dec 19;330(23):2304.

doi: 10.1001/jama.2023.21106.

¹ Nathan S. Kline Institute for Psychiatric Research, NYU Grossman School of Medicine, Orangeburg, New York.
² Research and Development, Chiesi Farmaceutici, Parma, Italy.

No abstract available

Comment on

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.